Founded in 2001, e-Therapeutics was listed on the AIM market of the London Stock Exchange in 2007. Its mission is to apply network pharmacology to find new treatments for human disease.

The company has a partnership with Danish diabetes giant Novo Nordisk, which was extended in August 2019.